Kurve Therapeutics | What We Do
Kurve Therapeutics’ patented Controlled Particle Dispersion (CPD)® technology significantly enhances the efficacy and dosage control of drug formulations by bypassing the blood-brain barrier.
Small as well as large, complex molecules have shown promise in treating neurodegenerative diseases, but other non-surgical technology — oral or intravenous — have seen little success in penetrating the blood-brain barrier. We have the answer to distributing medication to this targeted location through our technology’s enhanced reach into the brain.
Product Overview Video
The Controlled Particle Dispersion® device creates a precisely-controlled turbulent flow which allows medications to pass through the curved surfaces inside the nose and up to the olfactory mucosa at the top of the nasal cavity. This nose-to-brain region is where nerves penetrate to convey smell signals to the brain, but has historically been nearly impossible to deliver complex molecules to without the use of surgical methods.
Roughly one in six people — over one billion people — suffer from neurological disorders globally.
Family members and friends provided nearly $257 billion in unpaid care to people living with Alzheimer’s and other dementias in 2020. Not counting family care, the total national cost of caring for people living with Alzheimer’s and other dementias was projected to reach $355 billion in 2021.
Every 3 seconds, someone in the world develops dementia.
350,000 new cases of early-onset dementia occur globally every year. The number of Americans with the disease will increase to a projected 7.1 million people by 2025, an increase of nearly 22%.
The most common cause of dementia is Alzheimer’s disease, which accounts for roughly 60% to 80% of cases in the 55 million people living with dementia worldwide. This number is estimated to double every 20 years.
Parkinson’s disease is the second most common neurodegenerative disorder, with an estimated 9.4 million people suffering from the disease globally. Parkinson’s related surgery can cost a patient up to $100,000.
There are currently 2.8 million people diagnosed with Multiple Sclerosis, with nearly one million in the US alone.
There is strong evidence that diabetes increases the risk of cognitive impairment and dementia; people with diabetes have a 50–100% higher chance of being affected by dementia; this disease accelerates the aging of the brain by five years. As of 2021, there are 537 million people living with diabetes worldwide, with about 10.5% of the US population — 34.2 million — living with the disease. By 2045, the global number is expected to grow to 783 million diabetics.
Features and Benefits
Increases treatment efficacy through better access to targeted organs and/or tissues
Reduces systemic side-effects by ensuring less medication reaches non-targeted areas
Enhances the opportunity for bioavailability: delivers droplets that rest below the zone of ciliated action (the clearance mechanism of the nasal mucosa), allowing for longer residence time, which improves transferability and accelerates onset of action
Greater dosage precision through programmable electronic circuitry and advanced mechanics, which deliver the intended, precise amount of medication while enhancing concentration in the desired area within the nasal cavity
Exceptional patient compliance: Kurve’s CPD® device is non-invasive, simplified, and features user-friendly modes of administration, all of which encourage patient compliance and use while minimizing application errors
Odorless, tasteless, and painless delivery of medication
Device is pocket-size, lightweight, portable, and battery-powered
Medication administration made easy: a typical dosage is taken twice daily for about 15 seconds each time
Kurve Therapeutics’ Controlled Particle Dispersion® technology can help enhance treatment for a variety of neurodegenerative diseases with proven, disease-modifying clinical success. A full list of studies is available upon request.